4- tert- butyl- 2- hydroxycyclohexylmethacrylate
structure given in first source; a hydrophilic, bulky monomer used to make hydrogels
Also Known As:
TBCM; 2-Propenoic acid, 2-methyl-, 4-(1,1-dimethylethyl)-2-hydroxycyclohexyl ester
Networked: 3
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
1. | Jeong, Hyein:
1 article
(01/2022)
|
2. | Kim, Bum-Joon:
1 article
(01/2022)
|
3. | Kim, Dong Hyun:
1 article
(01/2022)
|
4. | Lee, Duhyung:
1 article
(01/2022)
|
5. | Lee, So-Young:
1 article
(01/2022)
|
6. | Seo, Hyejun:
1 article
(01/2022)
|
7. | Kgwaadira, Botshelo T:
1 article
(01/2020)
|
8. | Mudiayi, Tantamika-Kabamba:
1 article
(01/2020)
|
9. | Nkubito, Grace K:
1 article
(01/2020)
|
10. | Tshitenge, Stephane:
1 article
(01/2020)
|
Related Diseases
1. | Tuberculosis (Tuberculoses)
|
2. | Neoplasms (Cancer)
01/01/2022
- " Moreover, TBCM-induced DCs can also generate memory CD4 T cells and exert long-term tumor prevention effects. " 01/01/2022
- " In addition, subcutaneous injection of TBCM-activated DCs loaded with cell lysates led to reduced tumor mass, enhanced mouse survival and lowered tumor incidence in lung carcinoma (LLC) cell-bearing mice. " 01/01/2022
- " In conclusion, our findings suggest that TBCM (Rv1885c), a novel TLR4 agonist, could be used as an immunoadjuvant for DC-based cancer immunotherapy." 01/01/2022
- " Here, we investigated the potential of chorismate mutase (TBCM, Rv1885c), a putative Mycobacterium tuberculosis (TB) virulence factor, as an immunoadjuvant in DC-based tumor immunotherapy. "
|
3. | Carcinoma (Carcinomatosis)
|
4. | Body Weight (Weight, Body)
|
|
Related Drugs and Biologics
Related Therapies and Procedures